Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.
Name: Allopurinol
Name: Placebo
Description: Renal clearance as defined by amount excreted in 24 hours/AUC from 0-24 hours
Measure: Oxypurinol Renal Clearance Time: 24 hours (Urine collected 0-4 hrs,4-8 hrs,8-10 hrs,10-24 hrs post-dose)Description: Maximum percent change in uric acid after a single dose of allopurinol
Measure: Percent Change Uric Acid Time: 24 hoursDescription: Area under the concentration time curve from 0-24 hours following a single dose of allopurinol (i.e. Day 1 of both protocols)
Measure: Oxypurinol AUC Time: 24 hours (Collections at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24 hours post-dose)Allocation: Non-Randomized
Parallel Assignment
There is one SNP
The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics. --- Q141K ---
The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics. --- Q141K ---
The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics. --- Q141K --- --- Q141K ---